North China Pharmaceutical (NCPC)
Second-largest penicillin enterprise globally and the largest Chinese producer of penicillin, amoxicillin, 6-APA, and streptomycin. Annual capacity: 7,000–8,000 tonnes antibiotics, 5,000 tonnes intermediates.
pharmaceutical · input
Primary fermentation output from Penicillium chrysogenum; feedstock for enzymatic conversion to 6-APA nucleus used in all penicillin-class antibiotics.
3
Source countries
3
Companies
1
Goods affected
0
Claims on record
What depends on it
1 essential American goods rely on penicillin g (pen g) somewhere upstream in their supply chain.
Where it comes from
Share of global supply, by country.
| Country | Share of supply |
|---|---|
| CNChina | 82% |
| ATAustria/EU | 5% |
| INIndia | 5% |
Who makes it
3 companies produce penicillin g (pen g).
Second-largest penicillin enterprise globally and the largest Chinese producer of penicillin, amoxicillin, 6-APA, and streptomycin. Annual capacity: 7,000–8,000 tonnes antibiotics, 5,000 tonnes intermediates.
Major Chinese pharmaceutical conglomerate with world-class fermentation infrastructure. Key producer of penicillin G, cephalosporin APIs, and 6-APA. Operates large bioreactors in Shandong and Hebei.
Indian generic pharmaceutical company (NSE: AUROPHARMA; HQ Hyderabad, Telangana; ~$3.8B revenue); one of the world's largest generic API and finished dose manufacturers. Aurobindo holds INCB quota approvals for buprenorphine API manufacture in India and exports to regulated markets (US, EU). Aurobindo's controlled substance API operations leverage India's generic pharmaceutical industrial base to serve the post-patent-cliff buprenorphine/naloxone generic market. The company's API and formulation business spans more than 150 drug categories; buprenorphine is produced within its active pharmaceutical ingredients division alongside other Schedule II controlled substances (methadone, tramadol, fentanyl intermediates). Indian buprenorphine API production for export is constrained by INCB country-level quota allocations that limit the aggregate quantity India is authorized to manufacture annually. Aurobindo also produces buprenorphine/naloxone finished dose sublingual films and tablets at its US FDA-approved facilities, sourcing API from its own manufacturing or from other qualified suppliers.